OT mobile menu

Search form



Checkpoint Inhibitor May Help Improve Outcomes in Ovarian Cancer Patients

Avelumab trial in combination with and/or platinum-based chemotherapy for ovarian cancer currently recruiting patients. Image © BlueRingMedia/Shutterstock.com 

Recent Content

Researchers in Texas are now reporting they have developed drug-loaded synthetic nanoparticles that can distinguish lung cancer cells from healthy cells.

A 34-year-old woman presents with a coin lesion in the right upper lobe of the lung. What is your diagnosis?

The combination of dasatinib (Sprycel) and venetoclax (Venclexta) may have the potential to improve the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL), according to Oregon researchers.

Circulating breast tumor cells from patients can convert from HER2-negative to HER2-positive according to a study published in Nature.

Investigators at the University of Colorado Cancer Center and Yale University are now reporting in the journal Cancer Cell on a new understanding of the cancer suppressing gene RhoDGI2 and how it may be involved in metastatic bladder cancer.

If you’ve been in oncology long enough, you’ve likely seen the patient who presents with metastatic disease, gets first-line therapy, progresses, switches to second-line therapy, progresses again, and so on, with their cancer becoming increasingly more resistant to therapy.

Combining venetoclax (Venclexta, AbbVie and Genentech) plus a tyrosine kinase inhibitor targeting the BCR-ABL oncogene can eradicate chronic myeloid leukemia stem cells in a mouse model of the disease.

By clicking Accept, you agree to become a member of the UBM Medica Community.